Is Merck's Stock Price Already Reflecting Its True Value?

Merck's stock price has risen significantly in recent months due to its string of regulatory milestones. The FDA label update for WINREVAIR in pulmonary arterial hypertension and new approvals for KEYTRUDA-based regimens have been major contributors to this growth.

The company's 90-day share price return stands at 25.13%, while the year-to-date share price return is a notable 41.77%. Despite a small 30-day pullback of 1.08%, Merck's stock remains near its current price of $150.91, with a one-year total shareholder return of 94.27% signaling steady momentum.

Simply Wall St's DCF model suggests that Merck is currently trading at a steep discount to its intrinsic value, with a fair value of $235.29 per share. This significant gap raises questions about whether analysts are being too cautious in their estimates for the company's pipeline and margins.